Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anti‑epileptic (sodium channel blocker) presented as an intravenous solution for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other global markets. All batches meet EU pharmacopoeial specifications and are shipped under controlled conditions, ensuring consistent potency and safety for clinical use.

Lacosamide is an anti‑epileptic drug that modulates neuronal sodium channels.

- Partial‑onset seizures: Used as adjunctive therapy to reduce seizure frequency in patients with epilepsy. - Focal seizures: Provides additional seizure control when combined with other antiepileptic agents. - Refractory epilepsy: May be employed as part of combination therapy for patients not adequately controlled by other medications.

Adverse reactions associated with lacosamide may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Somnolence

Serious or Rare Side Effects: - Cardiac arrhythmia or atrial fibrillation - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Respiratory depression - Hepatic injury - Hypotension

Key safety considerations for lacosamide include the following precautions. - Renal impairment: dose may require adjustment in patients with reduced kidney function. - Cardiac conduction disorders: monitor ECG as lacosamide can affect PR interval. - Concomitant CNS depressants: increased risk of sedation and respiratory depression. - Pregnancy: limited data; use only if potential benefit justifies the risk. - Elderly patients: may be more sensitive to side effects, requiring careful monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lacosamide can interact with other medicines; notable interactions are grouped below.

Major Interactions (Avoid): - Co‑administration with other sodium channel blockers (e.g., carbamazepine) may increase toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can raise lacosamide plasma concentrations.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids) may enhance sedation. - Anticoagulants (e.g., warfarin) may have altered INR values. - Diuretics may affect renal clearance of lacosamide. - Hormonal contraceptives may have reduced effectiveness. - Alcohol consumption can increase dizziness.